Hunan Ouya Pharmaceutical, established in 2007, manufactures and trades chiral intermediates, digestive system, and cardiovascular system drug APIs, with GMP-compliant production for some of its API products and patented processes covering Biapenem intermediates, a mercaptotriazolium chloride intermediate, Cefoselis Hydrogen Sulfate, and industrial-scale prulifloxacin manufacturing. The company emphasizes mass production capability, rigorous quality control, and responsive customer service, distributing to markets across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa.
No comments available.
Leave your rating & comment